B+
Bull case
25%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
ZBIO
Zenas BioPharmaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Positive longer-term INDIGO and SunStone data, an on-time European filing and eventual FDA approval could support a broader obexelimab franchise. The reported June 30 cash, equivalents and investments balance was $673.9 million.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -10.0.
What can break
Amgen's approved UPLIZNA creates an established IgG4-RD competitor. Amgen announcement
Momentum
32
Value
41
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $40.00 · Bear $14.00Analysis 2026-09-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $47.88
Why
Momentum32 · Δ7d -8.9
Value41 · Δ7d -0.0
Sentiment46 · Δ7d -10.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -10.0.
Contradictions & invalidation
- • Amgen's approved UPLIZNA creates an established IgG4-RD competitor. Amgen announcement
- • Clinical-stage spending and launch preparation could increase financing or dilution pressure; a cash balance alone does not establish runway.
- • The valuation remains exposed to a concentrated clinical and regulatory path, launch execution, financing needs and competition from approved IgG4-RD therapy.
Catalyst clock
2026-09-29
Obexelimab prelaunch investor event
Lead driver: Sentiment · See AI snapshot
Momentum
32
8% active weight
Current posture
7d trendSoftening
Δ7d
-8.9
Δ21d
-21.5
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
46
45% active weight
Current posture
7d trendSoftening
Δ7d
-10.0
Δ21d
-2.1
Why this grade
Composite grade D. Momentum 31.5 / Value 40.6 / Sentiment 46.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-25. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$1.78B
Beta
-
Shares Out
65.18M
P/E (TTM) · Derived
-3.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.26
Rev YoY
-100.0%
EPS YoY
+41.6%
Gross Margin
+96.9%
Op Margin
-
Net Debt
-$263.23M
Current Ratio
9.93
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data